Cargando…

Efficacy of denosumab therapy for neurofibromatosis type 1 with osteoporosis and history of fractures: a case report

BACKGROUND: The natural history and pathogenesis of the skeletal abnormalities found in neurofibromatosis type 1 (NF1) are poorly understood, and the therapeutic options for these manifestations remain limited. This report first describes the clinical outcomes of denosumab treatment for a patient wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uehara, Masashi, Nakamura, Yukio, Takahashi, Jun, Kamimura, Mikio, Isobe, Fumihiro, Yamaguchi, Tomomi, Kosho, Tomoki, Uchiyama, Shigeharu, Suzuki, Takako, Kato, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052922/ https://www.ncbi.nlm.nih.gov/pubmed/30038498 http://dx.doi.org/10.2147/TCRM.S159668

Ejemplares similares

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)

Efficacy of denosumab therapy for a 21-year-old woman with Prader-Willi syndrome, osteoporosis and history of fractures: a case report
por: Uehara, Masashi, et al.
Publicado: (2019)

Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series
por: Kobayashi, Tsukasa, et al.
Publicado: (2018)

Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2018)

Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women
por: Nakamura, Yukio, et al.
Publicado: (2017)

Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
por: Kamimura, Mikio, et al.
Publicado: (2018)

Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study
por: Nakamura, Yukio, et al.
Publicado: (2015)

Denosumab significantly improves lumbar spine bone mineral density more in treatment-naïve than in long-term bisphosphonate-treated patients
por: Suzuki, Takako, et al.
Publicado: (2018)

Efficacy of denosumab therapy for a 12-year-old female patient with Williams syndrome with osteoporosis and history of fractures: a case report
por: Uehara, Masashi, et al.
Publicado: (2021)

A case series of pregnancy- and lactation-associated osteoporosis and a review of the literature
por: Nakamura, Yukio, et al.
Publicado: (2015)

Efficacy of Denosumab for Osteoporosis in Two Patients with Adult-Onset Still’s Disease—Denosumab Efficacy in Osteoporotic Still’s Disease Patients
por: Kumaki, Daiki, et al.
Publicado: (2018)

Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment
por: Nakamura, Yukio, et al.
Publicado: (2018)

Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis
por: Nakamura, Yukio, et al.
Publicado: (2017)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Joint Pain Undergoes a Transition in Accordance with Signal Changes of Bones Detected by MRI in Hip Osteoarthritis
por: Kamimura, Mikio, et al.
Publicado: (2013)

Painful locking of the wrist in a patient with pseudoachondroplasia confirmed by COMP mutation
por: Ideta, Hirokazu, et al.
Publicado: (2017)

Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

A Case with Atypical Clinical Course Diagnosed as Osteoarthritis, Osteonecrosis, Subchondral Insufficiency Fracture, or Rapidly Destructive Coxopathy
por: Nakamura, Yukio, et al.
Publicado: (2014)

The Pathophysiology and Progression of Hip Osteoarthritis Accompanied with Joint Pain are Potentially Due to Bone Alterations - Follow-up Study of Hip OA Patients
por: Kamimura, Mikio, et al.
Publicado: (2014)

The Pathophysiology of Primary Hip Osteoarthritis may Originate from Bone Alterations
por: Kamimura, Mikio, et al.
Publicado: (2013)

Bone alterations are associated with ankle osteoarthritis joint pain
por: Nakamura, Yukio, et al.
Publicado: (2016)

Monthly minodronate inhibits bone resorption to a greater extent than does monthly risedronate
por: Kamimura, Mikio, et al.
Publicado: (2016)

Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D(3) and alters values of parathyroid hormone, pentosidine, and bone metabolic markers
por: Kamimura, Mikio, et al.
Publicado: (2017)

Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients
por: Suzuki, Takako, et al.
Publicado: (2018)

Knee Joint Pain Potentially Due to Bone Alterations in a Knee Osteoarthritis Patient
por: Komatsu, Masatoshi, et al.
Publicado: (2014)

Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
por: Suzuki, Takako, et al.
Publicado: (2017)

Associations of self-reported height loss and kyphosis with vertebral fractures in Japanese women 60 years and older: a cross-sectional survey
por: Kamimura, Mikio, et al.
Publicado: (2016)

Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis
por: Kamimura, Mikio, et al.
Publicado: (2019)

Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

Comparison in bone turnover markers during early healing of femoral neck fracture and trochanteric fracture in elderly patients
por: Ikegami, Shota, et al.
Publicado: (2009)

Early Changes in Bone Specific Turnover Markers During the Healing Process After Vertebral Fracture
por: Hashidate, Hiroyuki, et al.
Publicado: (2011)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2018)

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2021)

Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study
por: Suzuki, Takako, et al.
Publicado: (2019)

Persistence of Denosumab Therapy among Patients with Osteoporosis
por: Kobayashi, Kazuyoshi, et al.
Publicado: (2020)

Anti-Nociceptive Effects of Elcatonin Injection for Postmenopausal Women with Back Pain: A Randomized Controlled Trial
por: Ikegami, Shota, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_aidtdibad5i5v92g81c45j9l2s